Search clinical trials for: Stage III/IV NSCLC

Total 18756 results

NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
NCIC Clinical Trials Group

Completed

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Colorectal Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Canada
Angela Moore
Almirall, SAS

Completed

Sarecycline Truncal Acne Safety and Efficacy Response (TASER)

Acne Vulgaris

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Stand Up To Cancer; Iovance Biotherapeutics, Inc.; Prometheus...

Completed

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Adenocarcinomas | Squamous Cell Carcinoma | Advanced NSCLC | Metastatic Non-small Cell Lung Cancer | Adenosquamous Carcinoma

United States
Fudan University

Completed

Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)

Non-small Cell Lung Cancer Stage I | Lymph Node Metastases

China
Fox Chase Cancer Center

Withdrawn

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Non-Small Cell Lung Cancer

United States
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China
Jeffrey Clarke

Completed

Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705)

Non-small Cell Lung Cancer

United States
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
AstraZeneca

Terminated

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. (ON TRAX)

Unresectable Stage III NSCLC

United States
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Sun Yat-sen University

Completed

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

Brain Metastases | NSCLC Stage IV | PD-1 Antibody

China
University of Alabama at Birmingham
Eli Lilly and Company

Completed

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Stage IV Non-Small Cell Lung Cancer

United States
The Netherlands Cancer Institute
Dutch Cancer Society

Terminated

Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis (HALO)

Lung Metastases | Lung Cancer Stage I | Lung Cancer Stage II

Netherlands
University of Texas Southwestern Medical Center

Completed

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Stage IV Non-Small Cell Lung Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Non-Small-Cell Lung Cancer

China
University of Wisconsin, Madison
AstraZeneca

Terminated

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV

United States
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
Radiation Therapy Oncology Group
Varian Medical Systems

Active, not recruiting

Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC (POSTILV)

Non-small Cell Lung Cancer

China
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
National Cheng-Kung University Hospital

Completed

Genomic Study in Non-small Cell Lung Cancer Brain Metastasis

Brain Metastases | NSCLC Stage IV

Taiwan
Rennes University Hospital

Completed

Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments (ESOGIA)

Non Small-cell Lung Cancer

France
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote-695)

Stage III/IV Melanoma

United States, Australia, Canada, Italy, Switzerland
National Cancer Institute, Naples

Active, not recruiting

PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy (PETRA)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
Niguarda Hospital
University of Turin, Italy; Fondazione del Piemonte per l'Oncologia

Completed

Donation of Post Mortem Tumor Tissues (DONUM)

NSCLC Stage IV | CRC | CUP

Italy
Eucure (Beijing) Biopharma Co., Ltd

Withdrawn

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)

HCC | NSCLC Stage IV | NSCLC Stage IIIB

China, Australia, Taiwan, Armenia, Austria
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
Bayer
Merck Sharp & Dohme LLC

Terminated

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Carcinoma, Non-Small-Cell Lung

Spain, Belgium, Netherlands, United States
Nasser Hanna
Genentech, Inc.

Terminated

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

NSCLC Stage IV | NSCLC, Recurrent

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus (LUCENCE)

Non-Small Cell Lung Cancer

Greece
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
Xiangya Hospital of Central South University

Active, not recruiting

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC

Non-small Cell Lung Cancer Stage III

China
H. Lee Moffitt Cancer Center and Research Institute
Array BioPharma

Completed

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Non-Small Cell Lung Cancer | Lung Cancer

United States
University of California, San Francisco
Novartis Pharmaceuticals; University of California, Davis

Terminated

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Nathan Pennell, MD, PhD

Terminated

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

Stage IIIA Non-Small Cell Lung Cancer

United States
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Regeneron Pharmaceuticals
Sanofi

Terminated

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, Italy, Lithuania
Bristol-Myers Squibb
PPD

Completed

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (Checkmate 171)

Non-Small Cell Lung Cancer

Poland, Spain, Austria, Denmark, Finland, Greece, Hungary, Ireland, Portugal, Romania, Russian Federation, Sweden, United Kingdom
University Medical Center Groningen

Completed

Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study (MRI-HART)

Pulmonary Hypertension

Netherlands
M.D. Anderson Cancer Center
Varian Medical Systems

Completed

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Lung Cancer

United States
Gruppo Oncologico Italiano di Ricerca Clinica
Bioikos Ambiente Srl; Istituto Toscano Tumori; Temas srl; Mipharm S.p.A.; Bristol...

Active, not recruiting

Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) (EDEN)

Squamous Non-small Cell Lung Cancer

Italy
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Jianguo Sun

Completed

Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.

Stage III Non-small-cell Lung Cancer
ETOP IBCSG Partners Foundation
Hoffmann-La Roche; AstraZeneca

Active, not recruiting

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) (BOOSTER)

Non Small Cell Lung Cancer Metastatic

Ireland, Singapore, Spain, Switzerland, Korea, Republic of, Netherlands
ETOP IBCSG Partners Foundation
Bristol-Myers Squibb; Frontier Science Foundation, Hellas

Completed

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

Non-small Cell Lung Cancer Stage III

Switzerland, Netherlands, Spain, Belgium, Germany
ETOP IBCSG Partners Foundation

Completed

Afatinib in NSCLC With HER2 Mutation (NICHE)

NSCLC

Switzerland, Germany, Spain, Netherlands

Search clinical trials for: Stage III/IV NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations